This is the text extract for 2012-05 Schedule Dispatch, browse documents here.

---

18 April 2012 May 2012 Pharmaceutical Schedule Dispatch This document is provided to pharmacists as an early notification of the changes to be announced in the May 2012 Update to the Pharmaceutical Schedule. Please notify PHARMAC (0800 66 00 50) to change or remove your contact details. New listings    Bisoprolol fumarate (Bosvate) tab 2.5 mg (p’code 2392844), 5 mg (p’code 2392852) and 10 mg (p’code 2392860) Propylthiouracil (PTU) tab 50 mg – Special Authority – Retail Pharmacy (p’code 2010526) (section 29) Brimonidine tartrate (Arrow-Brimonidine) eye drops 0.2%, 5 ml OP (p’code 2396513)

Changes to restrictions  Sodium chloride (Biomed) inj 23.4%, 20 ml - addition of oral standard formula for treatment of hyponatraemia  Ciclopiroxolamine – amend chemical name to ciclopirox olamine  Sunitinib (Sutent) – amended Special Authority  Lapatinib (Tykerb) – amend therapeutic subgroup to protein-tyrosine kinase inhibitors  Glaucoma preparations – removal of Prescribing Guidelines  Brinzolamide (Azopt) eye drops 1% – addition of stat dispensing  Bimatoprost (Lumigan) eye drops 0.03% – addition of stat dispensing  Latanoprost (Hysite) eye drops 50 µg per ml, 2.5 ml – addition of stat dispensing  Travoprost (Travatan) eye drops 0.0004% – addition of stat dispensing  Brimonidine tartrate with timolol maleate (Combigan) eye drops 0.2% with timolol maleate 0.5% – addition of stat dispensing Decreased subsidy

Chemical Presentation Fully subsidised brands Partially subsidised brands Actigall Ursosan* (Cap 250 mg) Metoprolol - AFT CR Myloc CR* Betaloc CR* Lopresor Lopresor Slow-Lopresor Betaloc Multichem* PSM Dalacin C Clindamycin ABM* Rizamelt* Octreotide MaxRx*

Ursodeoxycholic acid Metoprolol succinate

Cap 300 mg Tab long-acting 23.75 mg, 47.5 mg, 95 mg and 190 mg Tab 50 mg Tab 100 mg Tab 200 mg Inj 1 mg per ml, 1 ml Oint BP Cap hydrochloride 150 mg Tab orodispersible 10 mg Inj 50 µg per ml, 1 ml, 100 µg per ml, 1 ml and 500 µg per ml, 1 ml Page 1 of 2

Metoprolol tartrate

Zinc and castor oil Clindamycin Rizatriptan Octreotide (somatostatin analogue)

Maxalt Melt Hospira Sandostatin

A500932 - qA22815

---

Dornase alfa 

Nebuliser soln, 2.5 mg per 2 ml ampoule Note - there is no subsidy change for this brand.

Pulmozyme

Increased subsidy Chemical

Domperidone Acetylcysteine

Presentation

Tab 10 mg Inj 200 mg per ml, 10 ml

Fully subsidised brands

Motilium Martindale Acetylcysteine

Update on Diabetes Product proposal PHARMAC received 2660 submissions in response to our recent consultation on proposals for diabetes products. At present we are taking the time necessary to carefully work through, and fully understand, the detail of the feedback we have received. We are continuing to seek input and advice from diabetes patients, and other representative groups. We do not yet have a clear view on when a decision will be taken on the proposals; the timeframe will be led by our need to carefully consider the issues raised, and the time needed to make any changes to the proposals that are considered necessary before a decision can be made. PHARMAC Consultations relating to PSA PHARMAC has issued three proposals alongside the PSA as an enabler for the proposed contract. Please note that if the current proposal is altered significantly or does not proceed then we will review our proposals accordingly. Feedback for the proposed changes to the Pharmaceutical Schedule Rules is due this Friday, the 20th April and Review of Dispensing Frequency for Monthly Medicines and Additional Proposals relating to Dispensing Frequency Rule and Access Exemption Rule close on Friday the 26th April. Thanks for feedback received to date.

NB. For further details and magnitude of the above subsidy changes, please consult the online version of the Update to the Pharmaceutical Schedule at: www.pharmac.govt.nz/healthpros/Schedule.

A500932 - qA22815

Page 2 of 2